- £51.86m
- £67.43m
- £51.41m
- 47
- 59
- 67
- 61
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 6.43 | ||
| PEG Ratio (f) | 0.21 | ||
| EPS Growth (f) | 43.18% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.7 | ||
| Price to Tang. Book | 29.37 | ||
| Price to Free Cashflow | 6.76 | ||
| Price to Sales | 1.01 | ||
| EV to EBITDA | 7.23 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.62% | ||
| Return on Equity | 1% | ||
| Operating Margin | 5.15% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | £m | 20.21 | 30.08 | 32.76 | 43.98 | 51.41 | 51.8 | 66 | 22.33% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +109.71 | +155.32 | -20.19 | -58.08 | +49.2 | +196.1 | +43.18 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Venture Life Group PLC is a United Kingdom-based consumer self-care company. The principal activities of the Company are the development, manufacturing, and commercialization of healthcare products, including medical devices, food supplements and cosmetics for the ageing population. The Company's product portfolio includes products, such as the UltraDEX and Dentyl oral care product ranges; the Balance Activ range in the area of women's intimate healthcare; the Lift Glucose and Glucogel product ranges for hypoglycaemia; Gelclair, Xonrid, and Pomi-T for oncology support products provide symptomatic relief for some of the side effects associated with cancer and its treatment; the Procto-eze Plus product ranges for hemorrhoids, and other Dermatology products. The Company operates through two segments: Venture Life Brands and Customer Brands. The Company's subsidiaries include Venture Life Limited, Lubatti Limited, Periproducts Limited, HL Healthcare Ltd, and Venture Life Healthcare Ltd.
Directors
- Lynn Drummond NEC (61)
- Jerry Randall CEO
- Daniel Wells CFO (34)
- Giuseppe Gioffre CTR
- Gianluca Braguti EDR
- Sharon Daly EDR
- Peter Bream NED (54)
- Carl Dempsey NED
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- December 12th, 2005
- Public Since
- March 28th, 2014
- No. of Employees
- 165
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 128,057,312
- Address
- Unit 12, The Courtyard, Eastern Road, BRACKNELL, RG12 2XB
- Web
- https://www.venture-life.com/
- Phone
- +44 1344578004
- Contact
- Daniel Wells
- Auditors
- CLA Evelyn Partners Limited
Latest News for VLG
Upcoming Events for VLG
Venture Life Group PLC Annual Shareholders Meeting
Half Year 2025 Venture Life Group PLC Earnings Release
Similar to VLG
Alliance Pharma
London Stock Exchange
Animalcare
London Stock Exchange
AstraZeneca
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
BSF Enterprise
London Stock Exchange
FAQ
As of Today at 23:56 UTC, shares in Venture Life are trading at 40.50p. This share price information is delayed by 15 minutes.
Shares in Venture Life last closed at 40.50p and the price had moved by +4.38% over the past 365 days. In terms of relative price strength the Venture Life share price has outperformed the FTSE All Share Index by +0.28% over the past year.
The overall consensus recommendation for Venture Life is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreVenture Life does not currently pay a dividend.
Venture Life does not currently pay a dividend.
Venture Life does not currently pay a dividend.
To buy shares in Venture Life you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 40.50p, shares in Venture Life had a market capitalisation of £51.86m.
Here are the trading details for Venture Life:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: VLG
Based on an overall assessment of its quality, value and momentum Venture Life is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Venture Life is 88.00p. That is 117.28% above the last closing price of 40.50p.
Analysts covering Venture Life currently have a consensus Earnings Per Share (EPS) forecast of £0.04 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Venture Life. Over the past six months, its share price has underperformed the FTSE All Share Index by -3.17%.
As of the last closing price of 40.50p, shares in Venture Life were trading -3.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Venture Life PE ratio based on its reported earnings over the past 12 months is 6.43. The shares last closed at 40.50p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Venture Life's management team is headed by:
- Lynn Drummond - NEC
- Jerry Randall - CEO
- Daniel Wells - CFO
- Giuseppe Gioffre - CTR
- Gianluca Braguti - EDR
- Sharon Daly - EDR
- Peter Bream - NED
- Carl Dempsey - NED